Caxton Associates LP Sells 65,920 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Caxton Associates LP trimmed its position in Exelixis, Inc. (NASDAQ:EXEL) by 47.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 72,953 shares of the biotechnology company’s stock after selling 65,920 shares during the period. Caxton Associates LP’s holdings in Exelixis were worth $1,639,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Fisher Asset Management LLC raised its holdings in Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after buying an additional 728 shares during the period. Rise Advisors LLC acquired a new stake in Exelixis during the 1st quarter worth approximately $28,000. Park Place Capital Corp acquired a new stake in shares of Exelixis in the second quarter valued at approximately $45,000. GAMMA Investing LLC raised its holdings in shares of Exelixis by 107.9% in the second quarter. GAMMA Investing LLC now owns 2,006 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 1,041 shares during the last quarter. Finally, EntryPoint Capital LLC raised its holdings in shares of Exelixis by 537.2% in the first quarter. EntryPoint Capital LLC now owns 2,071 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 1,746 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Exelixis

In related news, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the completion of the transaction, the executive vice president now owns 605,325 shares of the company’s stock, valued at $15,968,473.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the business’s stock in a transaction dated Friday, August 9th. The stock was sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now owns 721,680 shares of the company’s stock, valued at $19,622,479.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the transaction, the executive vice president now directly owns 605,325 shares of the company’s stock, valued at approximately $15,968,473.50. The disclosure for this sale can be found here. Insiders sold a total of 327,858 shares of company stock valued at $8,640,129 over the last quarter. 2.85% of the stock is owned by corporate insiders.

Exelixis Stock Performance

Shares of Exelixis stock opened at $26.06 on Thursday. The firm has a 50-day moving average of $25.42 and a 200-day moving average of $23.43. The stock has a market cap of $7.43 billion, a PE ratio of 40.72, a PEG ratio of 0.56 and a beta of 0.54. Exelixis, Inc. has a 52-week low of $18.64 and a 52-week high of $27.83.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.44. The company had revenue of $637.18 million during the quarter, compared to analysts’ expectations of $468.21 million. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. Equities research analysts predict that Exelixis, Inc. will post 1.59 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EXEL has been the topic of a number of recent research reports. UBS Group initiated coverage on shares of Exelixis in a report on Thursday, September 19th. They issued a “neutral” rating and a $30.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Exelixis in a research note on Wednesday, September 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $27.00 target price on shares of Exelixis in a research note on Wednesday, August 7th. Truist Financial reissued a “buy” rating and issued a $33.00 target price (up from $32.00) on shares of Exelixis in a research note on Thursday, August 8th. Finally, JMP Securities reissued a “market outperform” rating and issued a $29.00 target price on shares of Exelixis in a research note on Friday, September 20th. Five analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis presently has an average rating of “Moderate Buy” and an average price target of $27.67.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.